• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.
【24h】

Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.

机译：儿童蜂毒免疫治疗过程中促进过敏原-IgE结合的血清抑制活性的时程。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Immunotherapy for bee venom allergy is effective and provides long-term protection. Venom-specific IgG4 levels are increased but with no correlation with clinical improvement. Following grass pollen immunotherapy, elevation of antigen-specific IgG4 is accompanied by increases in IgG-dependent serum inhibitory activity for IgE-facilitated binding of allergen-IgE complexes to B cells. As this 'functional' assay of inhibitory antibodies may be more predictive of clinical efficacy, we investigated the time course of serum inhibitory activity for IgE-facilitated antigen binding during venom immunotherapy (VIT) in children and following 2 years of VIT withdrawal. METHODS: Ten bee venom-allergic children (mean age: 9.3 years; m/f, 7/3) with moderate to severe allergic reactions to bee stings received VIT. A separate group of seven children (mean age: 14 years; m/f, 5/2) were investigated 2 years after VIT withdrawal. Ten age- and gender-matched children served as non-allergic controls. Allergen-specific serum IgG4 and IgE levels were measured by ELISA at baseline, after 2 years of VIT and 2 years after VIT withdrawal. Serum inhibitory activity was assessed using the facilitated-allergen binding (FAB) assay. RESULTS: Sera obtained during VIT significantly inhibited allergen-IgE binding to B-cells (pre-treatment=104+/-23%; 2 years=46+/-15%; P<0.001) when compared with sera obtained after treatment withdrawal and sera from normal controls. In parallel to FAB inhibition during VIT, significantly higher IgG4 levels were noted after immunotherapy (pre-treatment=8.6+/-2.3 AU; 2 years=26.7+/-3.5 AU; P<0.001) compared with those observed after withdrawal and in the controls. In contrast, progressively lower IgE concentrations were observed compared with pre-treatment (44+/-7 AU) in sera obtained after 2 years of VIT (25+/-5 AU; P<0.01) and 2 years following the withdrawal of VIT (10+/-3 AU; P<0.05). CONCLUSIONS: In contrast to grass pollen immunotherapy, the persistent decline in venom-specific IgE levels, rather than serum inhibitory activity for FAB, may be more relevant for long-term clinical efficacy of VIT.
机译：背景：对蜂毒过敏的免疫疗法是有效的，并提供长期保护。毒液特异性IgG4水平增加，但与临床改善无关。在草花粉免疫疗法之后，抗原特异性IgG4的升高伴随着针对IgE的变应原-IgE复合物与B细胞结合的IgG依赖性血清抑制活性的增加。由于这种抑制性抗体的“功能性”测定法可能更能预测临床疗效，因此我们研究了在儿童进行毒液免疫治疗（VIT）以及停药2年后，血清对IgE促进的抗原结合的血清抑制活性的时间过程。方法：对10名对蜂st有中度至重度过敏反应的蜂毒过敏儿童（平均年龄：9.3岁;男/女，7/3）接受VIT。退出VIT后2年，对另外7名儿童（平均年龄：14岁; m / f，5/2）进行了调查。十个年龄和性别相匹配的儿童作为非过敏对照。在VIT 2年后和VIT撤药2年后，通过ELISA在基线时测量过敏原特异性血清IgG4和IgE的水平。使用促进过敏原结合（FAB）分析评估血清抑制活性。结果：与停药后获得的血清相比，VIT期间获得的血清显着抑制了变应原-IgE与B细胞的结合（治疗前= 104 +/- 23％; 2年= 46 +/- 15％; P <0.001）。和正常对照血清。在VIT期间抑制FAB的同时，免疫治疗后的IgG4水平明显升高（预处理= 8.6 +/- 2.3 AU; 2年= 26.7 +/- 3.5 AU; P <0.001），与停药后和停药期相比。控件。相反，在VIT 2年后（25 +/- 5 AU; P <0.01）和VIT撤退2年后获得的血清中，与治疗前（44 +/- 7 AU）相比，观察到的IgE浓度逐渐降低。 （10 +/- 3 AU; P <0.05）。结论：与草花粉免疫疗法相比，毒液特异性IgE水平持续下降而不是血清对FAB的抑制活性可能与VIT的长期临床疗效更为相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号